Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    AKT1
Show Display Options
Rank Status Study
1 Recruiting Phase 1 Study of ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations or PTEN-null
Conditions: Cancer;   Solid Tumors
Intervention: Drug: ARQ 751
2 Recruiting Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Conditions: Advanced Solid Malignancy;   Safety and Tolerability;   Pharmacokinetics;   Pharmacodynamics;   Tumour Response;   Advanced or Metastatic Breast Cancer;   Ovarian Cancer;   Cervical Cancer;   Endometrial Cancer;   PIK3CA;   AKT1;   PTEN;   ER Positive;   HER2 Positive
Intervention: Drug: AZD5363
3 Active, not recruiting Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
Condition: Neoplasms
Intervention: Drug: BAY1125976
4 Recruiting NGS Genome Analysis in Personalisation of Lung Cancer Treatment
Condition: Lung Cancer
Intervention: Other: blood sample, biopsy
5 Enrolling by invitation Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome
Condition: Proteus Syndrome
Intervention: Drug: ARQ 092
6 Enrolling by invitation A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
Condition: Schizophrenia
Intervention:
7 Recruiting Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia
Condition: Tumor Induced Oncogenic Osteomalacia
Intervention:
8 Recruiting Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus
Condition: SOLID TUMOR
Intervention:
9 Completed
Has Results
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
10 Completed Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
Condition: Cardiovascular Abnormalities
Intervention: Drug: Sirolimus
11 Active, not recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
12 Recruiting Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care
Condition: Vascular Malformations
Intervention: Drug: Sirolimus
13 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Conditions: Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Rectal Mucinous Adenocarcinoma;   Rectal Signet Ring Cell Adenocarcinoma;   Recurrent Colon Carcinoma;   Recurrent Rectal Carcinoma;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
14 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
15 Active, not recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
16 Completed
Has Results
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Sarcoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis
17 Completed
Has Results
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab
18 Active, not recruiting Trametinib With GSK2141795 in BRAF Wild-type Melanoma
Condition: Melanoma
Interventions: Drug: Trametinib (GSK1120212);   Drug: GSK2141795
19 Active, not recruiting A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Conditions: Acute Lymphoblastic Leukemia;   Leukemia, Myelocytic, Acute;   Chronic Myelogenous Leukemia With Crisis of Blast Cells
Intervention: Drug: BEZ235
20 Recruiting A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Condition: Renal Cell Carcinoma
Intervention: Drug: RAD001

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.